First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
India’s first oncology laboratory for comprehensive Cancer Diagnostic services
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Tislelizumab is now approved in nine indications in China
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
The Accelerator will develop products and solutions that will support Sanofi’s mission to transform the practice of medicine with the use of digital, data and artificial intelligence (AI).
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Healthcare is timely and personal – and its delivery should be too
Based on a post hoc analysis, fewer required respiratory interventions
Subscribe To Our Newsletter & Stay Updated
